Treasury prices ended higher Friday, cementing a weekly decline for yields after the Federal Reserve on Wednesday failed to signal a more aggressive approach to future rate moves.
The yield on the 10-year Treasury note TMUBMUSD10Y, +0.00% fell 2.5 basis points to 2.506%, while the 2-year yield TMUBMUSD02Y, +0.00% declined 0.8 basis point to 1.316%. The yield on the 30-year Treasury bond TMUBMUSD30Y, +0.00% fell 2.6 basis points to 3.111%.
daily stock market: Federated Investors, Inc.(FII)
- [By Gregg Greenberg]
Stocks of Federated Investors (FII) fell approximately 9% in 2015, yet Oja expects a big turnaround in 2016, once again due to the prospect of higher rates ahead.
"The money market fund business, which is unprofitable now, should become more profitable as rates rise because Federated has to reimburse for the servicing fees for these funds," said Oja, who also admires the fund company’s 3.5% dividend yield.
Oja added that Federated also has a "good core business of equity and fixed-income asset management."
daily stock market: Harmony Gold Mining Company Limited(HMY)
- [By Lisa Levin]
In trading on Friday, basic materials shares tumbled by 1.20 percent. Meanwhile, top losers in the sector included McEwen Mining Inc (NYSE: MUX), down 6 percent, and Harmony Gold Mining Co. (ADR) (NYSE: HMY), down 6 percent.
- [By Javier Hasse]
Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 2.2 percent on Friday, even though gold prices dropped. However, the stock lost 3.7 percent in after-hours trading, in what also seemed like a correction of the surge seen during the day.
- [By Lisa Levin]
In trading on Thursday, basic materials shares fell by 0.73 percent. Meanwhile, top losers in the sector included Silver Wheaton Corp. (USA) (NYSE: SLW), down 5 percent, and Harmony Gold Mining Co. (ADR) (NYSE: HMY), down 5 percent.
- [By Lisa Levin]
On Wednesday, basic materials shares surged by 0.6 percent. Top gainers in the sector included Harmony Gold Mining Co. (ADR) (NYSE: HMY) and Gold Fields Limited (ADR) (NYSE: GFI).
daily stock market: MGT Capital Investments Inc(MGT)
- [By Lisa Levin]
MGT Capital Investments Inc. (NYSE: MGT) was down, falling around 24 percent to $2.47 as the company reported that it has received a subpoena from the Securities and Exchange Commission. MGT Capital said there is no indication that ‘the company is or will be the subject of any enforcement proceedings.’
- [By Lisa Levin]
MGT Capital Investments Inc. (NYSE: MGT) shares shot up 73 percent to $2.98 after John McAfee proposed to become Executive Chairman and CEO.
Shares of Anacor Pharmaceuticals Inc (NASDAQ: ANAC) got a boost, shooting up 55 percent to $99.49 after the company agreed to be acquired by Pfizer Inc. (NYSE: PFE) for $99.25 per share.
daily stock market: Facebook, Inc.(FB)
- [By Matthew Argersinger]
Chamath Palihapitiya of Social Capital sent murmurs (and several loud chuckles) through the crowd when he named Tesla (NASDAQ:TSLA) his top pick at this year’s conference. Palihapitiya, a former Facebook (NASDAQ: FB) executive and part owner of the NBA’s Golden State Warriors, made waves at last year’s conference when he called Amazon (NASDAQ: AMZN) a “10x opportunity in 10 years.”
- [By Mark Fritz]
Facebook Inc (NASDAQ: FB) on Tuesday published an explanation of its policy on “hate speech” that, if anything, shows just how hard it is for the company to accurately police a problem that goes far beyond social media.
- [By Sreekanth Anasa]
In its latest research report, eMarketer states that the search giant will maintain its dominance in digital ads taking in40.7% of US digital ad revenues in 2017more than double of what Facebook (NASDAQ:FB) would make. TheeMarketer research “expects Googles share of the search market to grow 16.1% to $28.55 billion in 2017. The search giant will claim roughly 78% of total US search ad revenues this year”.eMarketer forecasting analyst Monica Peart states that Google is set to benefit greatly from users’ behavioral shift to mobile search on increasing usage of smartphones. An important point to note here is that the ongoing ad fiasco is largely related toGoogle’s Display Network, where Google lags Facebook by some distance, but in that too eMarketer projectsDisplay Network revenue will rise to $5.24 billion in 2017. The above-cited research had just come recently before the YouTube ad exodus. However, as highlighted by the Morgan Stanley analyst above, the im pact on the Google’s bottom line due to current ad woes could be minimal and the above estimates may not vary in a drastic way.
- [By Sreekanth Anasa]
Menlo Park, California-based Facebook Inc (NASDAQ:FB)reported stellar last quarter earnings and is still one of the best growth stories out on there in the market. To continue its growth story, the social networking giant recently made its biggest move to make itself a one-stop destination for video content by announcing a standalone TV App for videos and other videofeatures on Facebook. Mark Zuckerberg is a big fan of videos and described ‘video’ as a “mega-trend”. In one of our previous posts, we had already covered how Facebook is posing a threat to Alphabet Inc’s(NASDAQ:GOOGL) YouTube. However, in a recent coverage on FB stock fellow Amigobulls contributor had discussed the headwinds faced by Facebook Inc and one of these headwinds coupled with the risks associated with the social media giant’s video push could hurt FB stock. Let’s take a closer look.
- [By Jack Delaney]
The annual Facebook Inc. (Nasdaq: FB) conference will start today (April 18, 2017), and the two-day event will cover 16 topics, some of which include:
daily stock market: Suncor Energy Inc.(SU)
- [By Shanthi Rexaline]
The six companies that met the criterion are:
Oshkosh Corp (NYSE: OSK). Phillips 66 (NYSE: PSX). SpartanNash Co (NASDAQ: SPTN). Suncor Energy Inc. (USA) (NYSE: SU). Washington Federal Inc. (NASDAQ: WAFD). Barnes & Noble, Inc. (NYSE: BKS). Oshkosh
Oshkosh is a manufacturer of specialty vehicles and vehicle bodies and is based in Wisconsin. The company operates under four business segments, namely access equipment, defense, fire and emergency, and commercial.
- [By Brian Feroldi, Chuck Saletta, Tyler Crowe, Jason Hall, and Jordan Wathen]
With that in mind, we asked a team of Fools each to highlight a stock that a billionaire investor has been selling recently. Read on to see why they chose Cheniere Energy (NYSEMKT:LNG), Activision Blizzard (NASDAQ:ATVI), Suncor Energy (NYSE:SU), MGIC Investment Corporation (NYSE:MTG), and Extended Stay America (NYSE:STAY).
- [By Matthew DiLallo]
In Canada, for example, the company and its partners Royal Dutch Shell (NYSE:RDS-A)(NYSE:RDS-B) and Suncor Energy (NYSE:SU) came up dry in their initial exploration attempts in the Shelburne Basin offshore Nova Scotia. The first noncommercial well forced Suncor Energy to write off 105 million Canadian dollars ($78.7 million) for its 20% stake in the well. Meanwhile, ConocoPhillips recorded a total of $187 million of dry hole expenses in Canada last year after it wrote off two wells.
daily stock market: Novo Nordisk A/S(NVO)
- [By Peter Graham]
A long term performance chart shows MannKind Corporation having once been a highflyerwhile the performance of large cap insulin and diabetes stockNovo Nordisk A/S (NYSE: NVO) has fallen off and small cap Insulet Corporation (NASDAQ: PODD) has actually performed better:
- [By Keith Speights]
Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.
- [By Brian Orelli]
Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.
- [By James E. Brumley]
When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.
In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.
While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.
As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’
- [By Paul Ausick]
Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.